20.5 C
New York
Monday, September 21, 2026

Novo Nordisk is a value trap, says UBS’ Michael Yee

Michael Yee, UBS senior pharma and biotech analyst, joins ‘Fast Money’ to share his take on the top players in the obesity drug market.

This post was originally published on this site

Subscribe
Notify of
0 Comments
Inline Feedbacks
View all comments

Stay Connected

148,415FansLike
396,312FollowersFollow
3,750SubscribersSubscribe

Latest Articles

0
Would love your thoughts, please comment.x
()
x